symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ENTA,9.92,0.452471,419462,208869568,0,9.42-62.06,0.24,"Enanta Pharmaceuticals, Inc.",USD,0001177648,US29251M1062,29251M106,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.enanta.com,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",Dr. Jay R. Luly Ph.D.,Healthcare,US,160,617 607 0800,500 Arsenal Street,Watertown,MA,02472,2.78395,49.2361,https://financialmodelingprep.com/image-stock/ENTA.png,2013-03-21,False,False,True,False,False
